| 1 |
<table width="100%" border="0" cellspacing="2"> |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
| 2 |
<tr> |
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
| 3 |
<td> |
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
| 4 |
<p><img src="p/110.jpg" width="150" height="95" align="left" vspace="5" hspace="3" border="1"><font size="2" face="Arial, Helvetica, sans-serif" color="#000080">This |
of PLIVA's healthcare turnover. This strategic goal for this continued investment |
| 5 |
year's Organic Chemistry Award Vladimir |
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
| 6 |
Prelog was presented to Valerije Vrcek, |
Commitment to a unique two-fold R&D strategy: discovery and development of novel |
| 7 |
Ph.D., a young scientist from the Faculty |
chemical entities and development of value added generics, is further supported |
| 8 |
of Pharmacy and Biochemistry in Zagreb for |
by PLIVA's licensing strategy.</p> |
| 9 |
his exceptional contribution to synthesis |
<p>PLIVA has focused its research expertise in two therapeutic areas: anti-infectives |
| 10 |
of nucleosides, understanding of carbocationic |
and anti-inflammatories, and through this "Smart Discovery Strategy" globally |
| 11 |
rearrangements and NMR spectroscopy of organic |
competitive results are expected. Research activities are focussing on the early |
| 12 |
molecules. The Vladimir Prelog Organic Chemistry |
phases of discovery and development only, while for advanced stages of development |
| 13 |
Award was established in 1996 as a means |
and marketing, strategic partnerships will be established. PLIVA's vision in |
| 14 |
of encouragement for young Croatian scientists |
research is to develop new drugs whose production will serve unmet medical needs |
| 15 |
in the field of organic chemistry. It was |
and will have commercial returns in line with PLIVA's growth targets. At present, |
| 16 |
founded by PLIVA and the Croatian Chemical |
there are three potential new drugs in PLIVA's pipeline.</p> |
| 17 |
Society to mark 90 years of the birth of |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198"></p> |
| 18 |
Vladimir Prelog, the renowned Croatian scientist |
<p>In development, superior results will be achieved by the in-house development |
| 19 |
and Nobel Prize Winner.This year's Organic |
of new molecules, the development of final pharmaceutical Rx or OTC drug forms, |
| 20 |
Chemistry Award Vladimir</font></p> |
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
| 21 |
<p><font size="2" face="Arial, Helvetica, sans-serif" color="#000080"> |
Strategy is based on decades of experience and expertise in new API development |
| 22 |
Prelog was presented to Valerije Vrcek, |
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
| 23 |
Ph.D., a young scientist from the Faculty |
in chemistry and the innovative improvement of existing drugs.</p> |
| 24 |
of Pharmacy and Biochemistry in Zagreb for |
<p>Our R&D strategy binds together a top quality international research team, |
| 25 |
his exceptional contribution to synthesis |
a network of strategic partnerships with multinational and biotech companies |
| 26 |
of nucleosides, understanding of carbocationic |
and a broad cooperation with various international universities and institutes. |
| 27 |
rearrangements and NMR spectroscopy of organic |
These activities are further supported by an independent body that consists |
| 28 |
molecules. The Vladimir Prelog Organic Chemistry |
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
| 29 |
Award was established in 1996</font><font size="2" face="Verdana, Arial, Helvetica, sans-serif" color="#000080"> |
Scientific Advisory Board.</p> |
| 30 |
</font></p> |
<p>During the year 2000, 5 new patent applications were submitted in Croatia: |
| 31 |
</td> |
TNF-a Inhibitors, New Coumarins, and Torasemide polymorphs; 6 new patent applications |
| 32 |
</tr> |
were submitted in the UK, resulting from the PLIVA-GlaxoWellcome joint macrolide |
| 33 |
<tr> |
project; 8 patents from the year 2000 and the previous year were also submitted |
| 34 |
<td height="2"> |
abroad as PCTs: Macrolides and Torasemide polymorphs. As well, PLIVA researchers |
| 35 |
<hr size="1" width="100%"> |
and scientists continue to publish and lecture in the professional media. </p> |
|
</td> |
|
|
</tr> |
|
|
<tr valign="top"> |
|
|
<td> |
|
|
<p align=justify><img height=100 hspace=3 |
|
|
src="p/str1.gif" width=150 align=left border=1 vspace="5"><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">Research |
|
|
and Development is central to both PLIVA's |
|
|
past and future success. For that reason, |
|
|
PLIVA pays careful attention to the organization |
|
|
of R&D activities, ensuring that research |
|
|
and development activities are closely aligned |
|
|
to the company's core business.<br> |
|
|
<br> |
|
|
The prime goal of research at PLIVA is the |
|
|
development of new chemical entities which |
|
|
can be developed into innovative medicines |
|
|
to combat illness and improve the quality |
|
|
of life for people around the world. Our |
|
|
researchers, assistants and lab technicians |
|
|
as well as all employees at PLIVA understand |
|
|
that our primary task is helping people.</font> |
|
|
<p align=justify><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">PLIVA's |
|
|
blockbuster antibiotic <b>azithromycin</b> |
|
|
is a good example of how the dedication |
|
|
of the PLIVA's R&D staff brought about |
|
|
the discovery and development of a medicine |
|
|
which is now fighting disease worldwide, |
|
|
sold as <b>Sumamed</b> by PLIVA and licensed |
|
|
to Pfizer which markets it as <b>Zithromax</b>. |
|
|
At this very moment, the staff of PLIVA's |
|
|
research institute are working on new, innovative |
|
|
and original medicines which will carry |
|
|
on PLIVA's battle against disease.</font> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr valign="top"> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70 height="66"><img height=90 |
|
|
src="p/portret_spaventi.gif" width=70 border=0></td> |
|
|
<td width=15 height="66"></td> |
|
|
<td valign=top align=left width=275 height="66"><br> |
|
|
<font face=Arial color=#000080 size=1>RADAN |
|
|
SPAVENTI, M.D., Ph.D.<br> |
|
|
Research & Development, Direcor<br> |
|
|
Management Board, Vice President for |
|
|
R&D<br> |
|
|
Phone: 3851/3781 078<br> |
|
|
Fax: 3851/370 3175<br> |
|
|
E-mail: <a |
|
|
href="mailto:radan.spaventi@pliva.hr">radan.spaventi@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70 height="86"><img height=81 |
|
|
src="p/portret_kovacevic.gif" width=70 |
|
|
border=0></td> |
|
|
<td width=15 height="86"></td> |
|
|
<td valign=top align=left width=275 height="86"><br> |
|
|
<font face=Arial color=#000080 size=1>KRUNOSLAV |
|
|
KOVACEVIC, Ph. D. Chem.<br> |
|
|
Research & Development, Deputy to |
|
|
Director<br> |
|
|
Phone: 3851/3781 105, 3781 027<br> |
|
|
Fax: 3851/3703 175<br> |
|
|
E-mail: <a |
|
|
href="mailto:kruno.kovacevic@pliva.hr">kruno.kovacevic@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70><img height=81 src="p/portret_kolega.gif" width=70 border=0></td> |
|
|
<td width=15></td> |
|
|
<td valign=top align=left width=275><br> |
|
|
<font face=Arial color=#000080 size=1>MARKO |
|
|
KOLEGA, M.D., Ph.M.<br> |
|
|
Research & Development, Deputy to |
|
|
Director (+ New Res. Institute Building)<br> |
|
|
Phone: 3851/3781 163, 3781 098<br> |
|
|
Fax: 3851/3703 175<br> |
|
|
GSM/Cell: 38598/289 283<br> |
|
|
E-mail: <a href="mailto:marko.kolega@pliva.hr">marko.kolega@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
</table> |
|
Parent Directory
| 
Revision Log
| 
Patch